Beyond Air, Inc. (XAIR), a medical device and biopharmaceutical company focused on nitric oxide therapies, on Wednesday announced that it has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement under Nasdaq Rule 5550(a)(2).
The extension allows Beyond Air until August 4, 2025, to bring its stock price above the $1.00 per share threshold.
The extension comes after the company's common stock failed to meet the required bid price in the previous 180-day period, which ended on February 4, 2025.
Beyond Air has indicated it plans to address the deficiency, potentially through a reverse stock split if necessary.
The company remains in compliance with other Nasdaq listing requirements and continues to trade under the symbol "XAIR" on the Nasdaq Capital Market.
Currently, XAIR is trading at $0.40 up by 4.12%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.